MC
BMRN icon

Mathes Company’s BioMarin Pharmaceuticals BMRN Stock Holding History

Mathes Company’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-2,950
Closed -$201K – 170
2014
Q1 		$201K Hold
2,950
– – 0.11% 160
2013
Q4 		$208K Buy
+2,950
New +$200K 0.11% 156

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Mathes Company's BMRN Position: Q2 2014 in Review

Mathes Company sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2014, closing a stake of 2,950 shares — an estimated $201K sold.

Mathes Company first reported a position in BMRN in Q4 2013 and held it in 2 quarters. The position peaked at $208K in Q4 2013. 321 funds tracked by Wall St. Rank hold BMRN as of Q2 2014.

  • Mathes Company reported no remaining BioMarin Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Mathes Company sold 2,950 BioMarin Pharmaceuticals shares in Q2 2014, an estimated $201K.
  • Mathes Company first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 2 quarters.
  • Mathes Company's BioMarin Pharmaceuticals position peaked at $208K in Q4 2013.
  • 321 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2014.

Based on Mathes Company's 13F filing for Q2 2014, filed 5 Aug 2014.